Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.10.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Sep. 30, 2018
Dec. 31, 2017
Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES                
Net Loss $ (6,275,000) $ (4,184,000) $ (17,943,000) $ (13,341,000)        
Adjustments to reconcile net loss to net cash used in operating activities:                
Depreciation and amortization     600,000 554,000        
Deferred tax benefit     (41,000) (40,000)        
Stock-based compensation     3,958,000 2,024,000        
Non-cash loss on disposal of assets     8,000 0        
Non-cash investment income     (63,000) 0        
Non-cash patent write-off     87,000 0        
Changes in assets and liabilities:                
Accounts receivable     (2,000) (9,000)        
Prepaid expenses and other current assets     206,000 (112,000)        
Other assets     (50,000) (3,000)        
Accounts payable     88,000 113,000        
Accrued expenses     (82,000) 86,000        
Accrued salaries and payroll related expenses     (437,000) 159,000        
Deferred revenue     46,000 (67,000)        
Deferred rent     47,000 (12,000)        
Net cash used in operating activities     (13,578,000) (10,648,000)        
CASH FLOWS FROM INVESTING ACTIVITIES                
Proceeds from sale of fixed assets     16,000 0        
Purchases of property and equipment     (865,000) (494,000)        
Expenditures for patents and domain names     (157,000) (244,000)        
Redemption of investments held-to-maturity     39,590,000 4,747,000        
Purchase of investments held-to-maturity     (48,411,000) 0        
Net cash provided by (used in) investing activities     (9,827,000) 4,009,000        
CASH FLOWS FROM FINANCING ACTIVITIES                
Net proceeds from the sale of common stock from private placement offering     0 15,025,000        
Net proceeds from the sale of common stock from underwritten public offering     21,190,000 0        
Proceeds from exercise of stock options     14,000 54,000        
Proceeds from exercise of warrants     260,000 0        
Net cash provided by financing activities     21,464,000 15,079,000        
Effects of exchange rates on cash, cash equivalents and restricted cash     (2,000) 6,000        
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS     (1,943,000) 8,446,000        
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period     19,624,000 5,184,000 $ 5,184,000      
CASH, CASH EQUIVALENTS AND RESTRICTED CASH — End of period 17,681,000 13,630,000 17,681,000 13,630,000 19,624,000      
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION                
Taxes Paid     3,000 1,000        
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES                
Issuance of common stock in settlement of liability     1,004,000 272,000        
Stock options issued in settlement of liability     0 580,000        
Property and equipment included in accounts payable     124,000 30,000        
Property and equipment included in accrued liabilities     282,000   0      
Patents included in accounts payable     32,000 33,000        
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents                
Cash and cash equivalents           $ 17,470,000 $ 19,524,000 $ 13,530,000
Restricted cash           0 100,000 100,000
Restricted cash           211,000 0  
Total cash, cash equivalents and restricted cash $ 17,681,000 $ 13,630,000 $ 19,624,000 $ 5,184,000 $ 5,184,000 $ 17,681,000 $ 19,624,000 $ 13,630,000